From ACAAI: Tapinarof Cream Shows Early Efficacy in Pediatric AD Regardless of Comorbidities

New data from a pooled sub-analysis of the ADORING 1 and 2 trials show that VTAMA® (tapinarof) cream, 1%, was associated with improvements in children aged 2 to 17 with moderate to severe atopic dermatitis (AD).

Results from the analysis, presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, included 654 children randomized to once-daily tapinarof or vehicle for 8 weeks. Among the highlighted results: 

• At week 8, measured response rates were 42.3% in children with comorbidities (vs. 11.8% vehicle, P < 0.0001) and 49.5% in those without (vs. 14.8% vehicle, P < 0.0001). 
• EASI-75 scores followed a similar trend, with improvements as early as week 2 and sustained through week 8 (P < 0.0001 in both groups).
• Patient-reported outcomes (POEM, total and sleep scores, etc.) improved by week 1.
• Sleep scores decreased in tapinarof groups compared to vehicle-treated children (P ≤ 0.0003). A ≥4-point reduction in PP-NRS itch was achieved by week 2 in more than half of patients using tapinarof, with sustained response through week 8.
• Adverse events were consistent with prior reports: folliculitis (7.8%), upper respiratory infection (4.6%), and headache (3.7%) were most common.

“These reassuring data show tapinarof cream provided early relief, including on bothersome symptoms such as itch, for children as young as 2 years of age with and without comorbidities,” said Luz Fonacier, MD, NYU Grossman Long Island School of Medicine, in a press release from Organon.